YXG-158 is an Androgen Receptor Degrader and CYP17A1 Inhibitor (IC50=100 nM) for the Treatment of Enzalutamide-Resistant Prostate Cancer. YXG-158 abrogated the hERG inhibition and exhibited excellent PK profiles. In vivo, YXG-158 effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited robust antitumor efficacy both in enzalutamide-sensitive (LNCaP/AR) and enzalutamide-resistant (C4-2b-ENZ) xenograft models
MedKoo Cat#: 124256
Name: YXG-158
CAS#: N/A
Chemical Formula: C30H36FN3O
Exact Mass: 473.2800
Molecular Weight: 473.64
Elemental Analysis: C, 76.08; H, 7.66; F, 4.01; N, 8.87; O, 3.38
The following data is based on the product molecular weight 473.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
